Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-06-07
2005-06-07
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C548S535000
Reexamination Certificate
active
06903075
ABSTRACT:
Compounds of Formula I are antagonists of VLA-4 and/or α4β7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders.
REFERENCES:
patent: 4350698 (1982-09-01), Gleason et al.
patent: 4482486 (1984-11-01), Brtnik et al.
patent: 5219851 (1993-06-01), Hamilton et al.
patent: 5229381 (1993-07-01), Doherty et al.
patent: 5424329 (1995-06-01), Boschelli et al.
patent: 5430023 (1995-07-01), Gesellchen
patent: 5439930 (1995-08-01), Seredenin et al.
patent: 5510332 (1996-04-01), Kogan et al.
patent: 5602099 (1997-02-01), Schiller
patent: 5688913 (1997-11-01), Arrhenius et al.
patent: 6291453 (2001-09-01), Ashwell et al.
patent: 6362341 (2002-03-01), Thorsett et al.
patent: 6423688 (2002-07-01), Thorsett et al.
patent: 6489300 (2002-12-01), Thorsett et al.
patent: 6492421 (2002-12-01), Thorsett et al.
patent: 6559127 (2003-05-01), Dappen et al.
patent: 6583139 (2003-06-01), Thorsett et al.
patent: 6586602 (2003-07-01), Thorsett et al.
patent: 0190852 (1986-08-01), None
patent: 0 337 549 (1989-06-01), None
patent: 0 443132 (1990-12-01), None
patent: 0 618 221 (1994-05-01), None
patent: 0 696 593 (1996-02-01), None
patent: WO 92/04369 (1992-03-01), None
patent: WO 95/15973 (1995-06-01), None
patent: WO 96/01644 (1996-01-01), None
patent: WO 96/06108 (1996-02-01), None
patent: WO 96/20216 (1996-07-01), None
patent: WO 96/22966 (1996-08-01), None
patent: WO 96/40641 (1996-12-01), None
patent: WO 96/40781 (1996-12-01), None
patent: WO 97/02289 (1997-01-01), None
patent: WO 97/03094 (1997-01-01), None
patent: WO 98/54207 (1998-12-01), None
patent: WO 99/06390 (1999-02-01), None
patent: 99/06391 (1999-02-01), None
patent: WO 99/06431 (1999-02-01), None
patent: WO 99/06432 (1999-02-01), None
patent: WO 99/06433 (1999-02-01), None
patent: WO 99/06434 (1999-02-01), None
patent: WO 99/06435 (1999-02-01), None
patent: WO 99/06436 (1999-02-01), None
patent: WO 99/06437 (1999-02-01), None
Dutta (Journal of Peptide Science 6, 321-324, 2000).
Komoriya, Akira (J. Biol. Chem. 266 (23), 15075-15079, 1991).
Haworth, Duncan (Br. J. Pharmacol. 126(8), 1751-1760, 1999).
Haubner (J. Am. Chem. Soc. 118, 7881, 1996).
Lin (J Med Chem 42, 920, 1999).
El-Naggar, Acta. Pharm. Jugosl 35, 15, 1985.
Gerardo Byk, et al.,Bioorganic&Medicinal Chemistry Letters, vol. 5, No. 22, pp. 2677-2682, (1995).
Journal of the Chinese Chemical Society, 1990, 37, 299-305, Selective Alkaline Protease Catalyzed Hydrolysis of Peptide Esters.
J. Serb. Chem. Soc. 52 (I) 17-24 (1987) Synthesis of Some 4-Methoxycimamic Acid-2-Sulphonylamino Acid Derivatives and their Antimicrobial Activity.
Proc. Indian nain. Sci-Acad., 60, A, No. 2, 1994, pp. 433-439 Synthesis and Antimicrobial Activity of Some New 7-Methoxy-4-Methylcoumarin-6-Sulphonyl-Amino Acid Derivatives (1993).
Acta Pharm. Jugosl. 33 (1983) 103-110 Synthesis and Biological Activity of Some New Quinoline-8-Sulphonylamino Acid and Dipeptide Derivatives.
Pharmazie, 1986 41(6), pp 378-81.
J. Med. Chem. 36(26) 1993 pp 4201-4207.
Bioorg. & Med. Chem. vol. 6 No. 21 1996 pp 2495-2500.
J. Med. Chem. 1997, 40 pp 3359-3368.
J. Med. Chem. 1995, vol. 38, No. 22 pp 4597-4614.
Pharmazie, 1986 41 (4)m, pp 233-235.
Durette Philippe L.
Hagmann William K.
MacCoss Malcolm
Mills Sander G.
Mumford Richard A.
Merck & Co. , Inc.
Rose David L.
Weber Jon
Yang Mollie M.
LandOfFree
Heterocyclic amide compounds as cell adhesion inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic amide compounds as cell adhesion inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic amide compounds as cell adhesion inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3508198